• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

3.565 -0.015 (-0.42%)
Streaming Delayed Price Updated: 1:22 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Alvotech further strengthens liquidity by securing term loan facility of $75 million
July 01, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
June 18, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
June 18, 2026
From Alvotech
Via GlobeNewswire
Alvotech (NASDAQ:ALVO) Q1 2026 Results Miss Estimates, Shares Drop Over 9% as Revenue and EPS Fall Short ↗
May 06, 2026
Via Chartmill
Alvotech (NASDAQ:ALVO) Reports Q4 Revenue Beat but Significant EPS Miss, Stock Falls on Weak Guidance ↗
March 18, 2026
Via Chartmill
News headline image
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
June 15, 2026
From Alvotech
Via GlobeNewswire
These stocks are moving in today's after hours session ↗
June 15, 2026
Via Chartmill
News headline image
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
June 15, 2026
From Alvotech
Via GlobeNewswire
News headline image
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock? ↗
June 12, 2026
Driving revenue growth and earnings growth are two different things. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions ↗
June 10, 2026
Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilars-focused company is entering a “critical inflection period” as it advances several limited-competition products through... 
Via MarketBeat
News headline image
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
June 08, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End ↗
June 05, 2026
Alvotech (NASDAQ:ALVO) is at an “inflection point” after more than a decade of investment in its biosimilar platform, Founder and Executive Chairman Róbert Wessman said at the Jefferies Global... 
Via MarketBeat
News headline image
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
June 04, 2026
From Alvotech
Via GlobeNewswire
News headline image
Main Results of 2026 Annual and Extraordinary General Meeting
June 03, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to present at upcoming investor conferences in June
June 02, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech (ALVO) Q4 2025 Earnings Transcript ↗
June 02, 2026
Alvotech (ALVO) Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Bonds
News headline image
Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End ↗
May 13, 2026
Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilar developer is preparing to resubmit three biologics license applications to the U.S. Food and Drug Administration in June... 
Via MarketBeat
News headline image
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
May 11, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech (ALVO) Q1 2026 Earnings Transcript ↗
May 08, 2026
Alvotech (ALVO) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Alvotech Q1 2026 Financial Results
May 06, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces a Change in its Executive Team
April 30, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Report Financial Results for the First Quarter of 2026
April 24, 2026
From Alvotech
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
April 07, 2026
Via Chartmill
News headline image
Alvotech Files Annual Report with the SEC
March 30, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Q4 2025 and Full Year 2025 Financial Results
March 18, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
March 04, 2026
From Alvotech
Via GlobeNewswire
News headline image
ALVO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alvotech
February 23, 2026
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
Why Is ALVO Stock Rising Pre-Market Today? ↗
February 05, 2026
The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints. 
Via Stocktwits
News headline image
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
February 05, 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
February 02, 2026
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap